Boehringer takes alteplase to phase 3 for COVID, but drops antibodyBoehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its Share XBoehringer takes alteplase to phase 3 for COVID, but drops antibodyhttps://pharmaphorum.com/news/boehringer-takes-alteplase-to-phase-3-for-covid-but-drops-antibody/
Biogen bolsters ischaemic stroke pipeline with thrombolytic from TMSBiogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance Share XBiogen bolsters ischaemic stroke pipeline with thrombolytic from TMShttps://pharmaphorum.com/news/biogen-bolsters-ischaemic-stroke-pipeline-with-thrombolytic-from-tms/
